Aerami Therapeutics Holdings, Inc.
Aerami is a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions. In addition to AER-901, in development for PAH, the company’s cardiometabolic portfolio includes drug-device combination product candidates in Types 1 and 2 diabetes, which leverage Aerami’s proprietary AFINATM inhaler technology. Our product candidates have not been approved by any regulatory authority, and their safety, efficacy or other desirable attributes have not been established.
Commitment That’s Easy to Take In
Aerami Therapeutics is a clinical stage biopharmaceutical company engaged in the development of differentiated inhaled therapies for the treatment of cardiopulmonary and cardiometabolic conditions.
Breathing life into the treatment of cardiopulmonary and cardiometabolic diseases.
Each of our current product candidates is based on targeted molecules with promising clinical or preclinical track records and/or data sets within targeted indications, enabling focused and efficient development plans. We aim to combine these therapies with advanced administration platforms to develop differentiated medicines with the goal of extending and improving patients’ lives, preventing disease development or progression.